Patient Characteristics
| . | Diagnosis . | Age . | Conditioning* . | GVHD Prophylaxis† . | GVHD Grade/Onset . | Methylprednisolone‡ . | Chronic GVHD . | CSA Duration (mo) . | CMV Viremia . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CML | 13 | Cy + TBI(12) + TT | II/d 22 | 6/24 | 0 | 6 | + | |
| 2 | CML | 23 | Cy + TBI(13.5) + TT | CyA+ | II/d 19 | 2/20 | Yes1-153 | 11 | − |
| 3 | CML | 26 | Cy + TBI(12) | MTX+ | 0/− | 4/0 | Yes1-155 | 24 | − |
| 4 | AML | 20 | Cy + TBI(13.5) | Campath 1G | I/d 18 | 0/20 | 0 | 11 | − |
| 5 | ALL | 31 | Cy + TBI(12) | 0/− | 0/5 | 0 | 4 | − |
| . | Diagnosis . | Age . | Conditioning* . | GVHD Prophylaxis† . | GVHD Grade/Onset . | Methylprednisolone‡ . | Chronic GVHD . | CSA Duration (mo) . | CMV Viremia . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CML | 13 | Cy + TBI(12) + TT | II/d 22 | 6/24 | 0 | 6 | + | |
| 2 | CML | 23 | Cy + TBI(13.5) + TT | CyA+ | II/d 19 | 2/20 | Yes1-153 | 11 | − |
| 3 | CML | 26 | Cy + TBI(12) | MTX+ | 0/− | 4/0 | Yes1-155 | 24 | − |
| 4 | AML | 20 | Cy + TBI(13.5) | Campath 1G | I/d 18 | 0/20 | 0 | 11 | − |
| 5 | ALL | 31 | Cy + TBI(12) | 0/− | 0/5 | 0 | 4 | − |
Conditioning: Cy, cyclophosphamide (120 mg/kg); TBI, (Gy); TT, thiotepa (10 mg/kg).
All 5 patients received CyA (cyclosporin), MTX (methotrexate), and Campath 1G in vivo (for details see Patients, Materials, and Methods).
Days of high-low-dose methylprednisolone (>2 mg/kg)/≤2 mg/kg).
Localized (liver).
Localized (bronchiolitis obliterans).